Patient Characteristics to Consider for Doublet, Triplet Therapy in mHSPC and mCRPC

3 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
In the second segment of this roundtable discussion, David Morris, MD, FACS; John Phillips, MD; Jeremy McDuffie, MD; Katy Beckermann, MD, PhD; and Alan Tan, MD, discuss key considerations for patient selection in doublet and triplet therapies for metastatic hormone-sensitive and castration-resistant prostate cancer. The panel examines pivotal factors such as disease volume, comorbidities, treatment tolerability, and the impact of chemotherapy on future treatment options. Other topics include practical approaches to tailoring care for diverse patient populations, including those in rural settings, and balancing efficacy and quality of life in advanced prostate cancer management.
Category
Urology
Be the first to comment

Up Next